These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 18162361)
1. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361 [TBL] [Abstract][Full Text] [Related]
2. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Landsberger M; Jantzen F; Könemann S; Felix SB Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089 [TBL] [Abstract][Full Text] [Related]
3. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice]. Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423 [TBL] [Abstract][Full Text] [Related]
4. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Ii M; Nishimura H; Kusano KF; Qin G; Yoon YS; Wecker A; Asahara T; Losordo DW Circulation; 2005 Jul; 112(1):93-102. PubMed ID: 15983249 [TBL] [Abstract][Full Text] [Related]
5. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646 [TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896 [TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. Li W; Asagami T; Matsushita H; Lee KH; Tsao PS J Pharmacol Exp Ther; 2005 May; 313(2):557-62. PubMed ID: 15665143 [TBL] [Abstract][Full Text] [Related]
8. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148 [TBL] [Abstract][Full Text] [Related]
9. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Sukhanov S; Higashi Y; Shai SY; Vaughn C; Mohler J; Li Y; Song YH; Titterington J; Delafontaine P Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2684-90. PubMed ID: 17916769 [TBL] [Abstract][Full Text] [Related]
10. Statin treatment and 3' polyadenylation of eNOS mRNA. Kosmidou I; Moore JP; Weber M; Searles CD Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2642-9. PubMed ID: 17916773 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Schroeter MR; Humboldt T; Schäfer K; Konstantinides S Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832 [TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Pelat M; Dessy C; Massion P; Desager JP; Feron O; Balligand JL Circulation; 2003 May; 107(19):2480-6. PubMed ID: 12719275 [TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Famer D; Crisby M Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542 [TBL] [Abstract][Full Text] [Related]